AllTrials

[citation needed] Much medical research is done by the pharmaceutical industry, which have a conflict of interest reporting results which may hurt sales of their products.

It also biases the medical literature, making it report effects where none exist (since, given enough trials, eventually one will find a difference by pure chance).

[8][9] Ben Goldacre, a physician and spokesperson for the campaign, would like to address the systematic flaws in clinical research which cause data to be lost after it is gathered.

[21] There has been criticism from the Pharmaceutical Research and Manufacturers of America (PhRMA), with senior vice-president Matt Bennett saying that trial data disclosure measures which AllTrials has recommended to the European Medicines Agency "could risk patient privacy, lead to fewer clinical trials, and result in fewer new medicines to meet patient needs and improve health.".

A 2012 editorial published by senior regulators from the European Medicines agency[24] largely agreed with AllTrials, saying "We consider it neither desirable nor realistic to maintain the status quo of limited availability of regulatory trials data".

However, they warned that third party reanalysis was neither a guarantee of quality nor of lack of conflict of interest, which, in the worst case, could lead to negative public health consequences.

[citation needed] They suggested that reanalyses should therefore be subject to the same regulations as sponsor analyses, such as registering analysis plans.

[24] AllTrials is not calling for completely unrestricted access to raw data,[23] so the scope of disagreements is limited to what restrictions should be in place.

The petition statement of AllTrials has been signed by organizations including Wellcome Trust,[30] British Library, Medical Research Council (UK), British Heart Foundation, Institute for Quality and Efficiency in Health Care, National Institute for Health and Care Excellence, BioMed Central,[31] National Physicians Alliance, Royal Society of Medicine, Health Research Authority, American Medical Student Association, GlaxoSmithKline,[32] and others.

[33] In October 2016, AllTrials published a road map detailing steps that various types of organisations can take to get more trials registered and more results reported.